-

Synthace's New Report Reveals Challenges and Opportunities in Life Science R&D Experiments

LONDON & BOSTON--(BUSINESS WIRE)--Synthace, the leading digital experiment platform for life science R&D teams, has released a comprehensive analyst report titled Lab automation & experimentation in life science R&D 2023-2024. The report sheds light on the industry challenges faced by researchers and highlights opportunities for improvement. By addressing key themes such as data management, automation hurdles, burdens placed on individual scientists, and lack of support, Synthace aims to pave the way for more efficient and impactful experimentation.

The report can be downloaded here.

Decision makers lack confidence in their experiment data

The report delves into the critical role that accurate and reliable data plays in decision-making processes within the field. Surprisingly, 43% of decision-makers admit that their main difficulty in making clear go/no-go decisions lies with their confidence in experiment data. This statistic underscores the pressing need for improved processes, behaviors, and systems for data creation, management, and analysis that enable scientists to make informed choices based on robust evidence.

Furthermore, an overwhelming majority (90%) of decision-makers agree that hardware/software integration remains a significant barrier to digital transformation. Bridging this divide is crucial to unleash the full potential of laboratory automation tools and make scientific progress across research teams.

Key themes from the report

One major challenge highlighted by the report is scientists' struggle to build upon previous experiments due to difficulties accessing relevant information from different sources including literature reviews or equipment specifications. A staggering 57% of scientists face obstacles when attempting to leverage existing knowledge or replicate methods used by other researchers. Streamlining access to past work will undoubtedly enhance collaboration within scientific communities and accelerate progress.

Implementation time is another obstacle inhibiting innovation in laboratories worldwide. Approximately half (50%) of scientists cite lengthy implementation periods as a significant deterrent when considering new automation tools. Overcoming this hurdle would empower researchers with cutting-edge technologies while minimizing disruption during adoption phases.

"The findings presented in our report shed light on some fundamental challenges facing life science R&D experimentation today," said Markus Gershater Ph.D., Chief Scientific Officer at Synthace. "While we recognize there's no silver bullet solution, we remain committed to equipping teams with the tools and systems they need to navigate the complexities of their work. Our mission is to empower scientists, streamline experimentation processes, and drive impactful discoveries."

Additionally, the report highlights that reproducibility plays a critical role in optimizing resource allocation. 82% of decision-makers agree that more reproducible experiments would result in significant savings of time, money, and valuable resources.

Keeping track of diverse experimental elements presents yet another hurdle for researchers. An overwhelming majority (87%) of scientists admit that this is one of their key challenges.

Highlight statistics from the report:

  • 43% of decision-makers say the main difficulty with making clear go/no-go was confidence in experiment data
  • 90% of decision-makers agree that hardware/software integration creates a barrier to digital transformation
  • 57% of scientists have a hard time building on the work of previous experiments (lit, labs, scientists, equipment)
  • 50% of scientists report the main barrier to introducing new automation tools is implementation time and getting up to speed
  • 82% of decision-makers also agree that more reproducible experiments would lead to savings in time, money, and resources
  • 87% of scientists say the main challenge with running experiments is keeping track of all of the different elements involved
  • 52% of decision-makers believe that one of the main barriers to digital transformation in their labs is pushback from lab-based scientists

About Synthace

Synthace is a digital experiment platform built for life science R&D teams to help them run more powerful experiments. It digitizes experiments from end to end: with minimal training, scientists can design and plan reproducible experiments, simulate them ahead of time, run them on their automation equipment, and automatically structure all of their experimental data and metadata in a single place. Controlled from a browser window and needing no code to operate, it makes experiments easier to run in the lab, increases the scientific value of experiments, and also makes it possible to run experiments that were previously thought impossible. To learn more visit: http://www.synthace.com/

Contacts

Courtney Glymph
+44(0)7867488769
courtney@yourstorypr.com

More News From Synthace

 Synthace combines ChatGPT and digital experiments in first step toward a true AI scientist

LONDON & BOSTON--(BUSINESS WIRE)--Synthace, creators of the world’s first digital experiment platform for life science R&D, today announces the successful integration of their platform with OpenAI’s ChatGPT. This revolutionary development lets scientists use a natural language interface to describe their intent, use the AI to design complex experiments, and then run those experiments on lab equipment. Watch the video here: https://www.youtube.com/watch?v=IPwI6Us57iM At a glance: what Syntha...

Synthace, a Digital Experiment Platform for Life Science R&D, Records Strongest Year Yet

LONDON & BOSTON--(BUSINESS WIRE)--Today, Synthace, a digital life science experiment platform, announces it has had its most successful year on record with major adoption and expansion with customers, industry recognition, product innovation, and a key hire at board level. Major adoption and expansion among the top 100 pharma Synthace experienced 94% annual recurring revenue growth, 166% year-on-year growth in total contract value, and 170% net revenue retention (NRR) growth among customers. Tr...

Synthace Appoints Dr. Donald Deieso as New Board Chair

LONDON & BOSTON--(BUSINESS WIRE)--Synthace, creators of the world’s first digital life science experiment platform, today announced the appointment of Dr. Donald Deieso as the new Chairman of their Board. Dr. Deieso steps into this role at a time of strong momentum for the company. After closing their Series C funding round last year, Synthace has doubled their year-on-year ARR and expanded to include 8 of the world’s top 12 pharmaceutical companies. “I speak for the entire company when I say t...
Back to Newsroom